ALPINE IMMUNE SCIENCES, INC.
alpineimmunesciences.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 9, 2024. Its latest SEC filing is a SC 13G/A from Nov 14, 2024.
10-Q for Q1 FY2024, filed May 9, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops protein-based immunotherapies for people with autoimmune and inflammatory diseases.
10-K for FY2023, filed Mar 20, 2024We are a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies to…View ↗
How Did They Make Money?
Collaboration partners pay Alpine upfront or option fees; Alpine also earns revenue for research and development services over the work period, when milestones are achieved, and from royalties on future product sales.
10-K for FY2023, filed Mar 20, 2024Our collaboration agreements principally contain multiple performance obligations, which may include (1) grants of, or options to obtain…View ↗
We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone…View ↗
Our collaboration agreements provide for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of…View ↗
$58.9M
-
10-K for FY2023, filed Mar 20, 2024
$58.9M ↗
Who Were Their Customers?
Alpine works with biopharmaceutical partners including AbbVie, Amgen and Adaptimmune under collaboration agreements for licenses and research services.
10-K for FY2023, filed Mar 20, 2024Our collaboration agreements principally contain multiple performance obligations, which may include (1) grants of, or options to obtain…View ↗
In December 2021, we entered into an exclusive license and collaboration agreement with Horizon Therapeutics Ireland DAC, (acquired by…View ↗
Our scientific platform has also generated immune modulatory proteins with the potential of improving engineered cell therapies such as…View ↗
Did Revenues Turn Into Profits?
No. It lost $32.2M in FY2023.
10-K for FY2023, filed Mar 20, 2024
−$44.3MView ↗
10-K for FY2023, filed Mar 20, 2024
−$32.2MView ↗
10-K for FY2023, filed Mar 20, 2024
−$79.5MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2024, filed May 10, 2024
−$17.9MView ↗
- ▲ +35% (Loss)
- vs −$13.3M in Q1 FY2023
-
May 20, 2024
Alpine's merger closed and changed control
The buyer acquired 100% of the voting securities; former stockholders retained only a right to receive merger consideration.
Sources
8-K, filed May 20, 2024
As a result of the consummation of the Offer and the Merger, there was a change in control of the Company, and Parent, as the direct parent…View ↗
-
Apr 10, 2024
Vertex agreed to acquire Alpine for cash
The merger agreement set a cash offer of $65 per share, subject to closing conditions.
Sources
8-K, filed Apr 10, 2024
On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), Adams Merger Sub, Inc., a Delaware…View ↗
Grew. Revenue grew 33.8x in 4 years, from $1.7M in FY2019 to $58.9M in FY2023, about 141% a year.
Focus shifts from cancer
The earlier report describes cancer alongside autoimmune and inflammatory disease and an active oncology program; the later report centers on autoimmune and inflammatory conditions and says enrollment in davoceticept's cancer studies ended.
10-K for FY2020, filed Mar 18, 2021 10-K for FY2023, filed Mar 20, 2024We are a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies to…View ↗
Our goal is to discover and develop modern therapies to treat patients with serious autoimmune and inflammatory diseases. To achieve our…View ↗
Davoceticept is a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. In October 2022, we…View ↗
Who Did They Compete With?
Competes with OSE ImmunoTherapeutics, Veloxis Pharmaceuticals, Asahi Kasei, AtoxBio, Bristol Myers Squibb, Zura Bio, GSK, Vera Therapeutics, RemeGen, Novartis, Visterra, Amgen, Macrogenics, Xencor, Zymeworks, Pieris Pharmaceuticals, Compass Therapeutics, Harpoon Therapeutics, Shattuck Labs, and Ablynx
10-K for FY2023, filed Mar 20, 2024an anti-CD28 monoclonal antibody fragment being developed by OSE ImmunoTherapeutics SA and Veloxis Pharmaceuticals Inc., a subsidiary of…View ↗
Loading...
